NR1H4 and Hepatic fibrosis: This suggested that TACS might reduce liver fibrosis by increasing CDCA levels, activating the FXR-FGF15 signaling pathway, and inhibiting liver bile acid synthesis, thereby reducing the accumulation of BAs in the liver.